High Flow Nasal Cannula Therapy for Early Management of Acute Hypercapnic Cardiogenic Pulmonary Edema in the Emergency Department

CompletedOBSERVATIONAL
Enrollment

32

Participants

Timeline

Start Date

February 1, 2015

Primary Completion Date

September 1, 2016

Study Completion Date

September 30, 2016

Conditions
Acute Cardiogenic Pulmonary EdemaHypercapnic Respiratory Failure
Interventions
DEVICE

High flow nasal therapy (HFNT) : Optiflow™

"HFNT will be administered through a heated humidifier (Airvo 2, Fisher and Paykel healthcare) and applied through large bore binasal prongs.~Initial gas flow rate will be set at of 60 l/min and adjusted to 40-50 l/min based on patient's tolerance. FiO2 will be adjusted to maintain an SpO2 ≥ 92%. Initial temperature will be set at 37° and reduced according to patient's tolerance"

DEVICE

Non invasive ventilation (niv)

"NIV will be delivered through a face mask connected to a dedicated ventilator with pressure support applied in a noninvasive ventilation mode (Monnal T75, Airliquide Medical Systems, Antony, France).~The Pressure-support level will be adjusted to obtain an expired tidal volume of 6-8 ml/kg of predicted body weight and a respiratory rate of 25-30 b/min. PEEP (range 5-10 cm of water) and FiO2 will be adjusted to maintain an SpO2 ≥92% and to patient's comfort."

Trial Locations (1)

34295

Uhmontpellier, Montpellier

All Listed Sponsors
collaborator

Fisher and Paykel Healthcare

INDUSTRY

lead

University Hospital, Montpellier

OTHER

NCT03883555 - High Flow Nasal Cannula Therapy for Early Management of Acute Hypercapnic Cardiogenic Pulmonary Edema in the Emergency Department | Biotech Hunter | Biotech Hunter